Pharma stocks in focus

With India recording almost 1.70 lakh Covid cases yesterday, naturally, for the stock market this is an opportunity to once again cash-in on the pharma stocks which could possibly gain in this deadly second wave.

The gainers include companies making Remdesivir, where exports have now been banned given the surging demand in India itself; then there are the labs working over time to conduct RT-PCR tests,

Thus the second wave has become a reason to celebrate for companies like AstraZeneca, Ipca Labs, Lal Path Labs, Cipla, Dr.Reddy’s , Suven Life Sciences, Divi’s Labs, Thyrocare, Torrent Pharma, Zydus Wellness; almost every single pharma stock is up in the green, headlining the list of gainers.

Yes Covid-led opportunities galore is what the stock market is looking at today while the broader market is down in the red, worried about the pandemic impacting growth in the coming months.